OneDigital Investment Advisors LLC Takes Position in Celcuity, Inc. $CELC

OneDigital Investment Advisors LLC bought a new stake in Celcuity, Inc. (NASDAQ:CELC) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 7,031 shares of the company’s stock, valued at approximately $736,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. NEA Management Company LLC lifted its position in Celcuity by 64.9% during the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after acquiring an additional 1,391,300 shares during the period. Avoro Capital Advisors LLC acquired a new position in shares of Celcuity in the fourth quarter valued at about $310,302,000. Soleus Capital Management L.P. raised its stake in shares of Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after purchasing an additional 437,696 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Celcuity by 10.7% in the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after purchasing an additional 220,386 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Celcuity by 126.6% in the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after purchasing an additional 914,887 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

NASDAQ CELC opened at $93.24 on Wednesday. The stock has a 50-day simple moving average of $94.00 and a two-hundred day simple moving average of $108.08. The firm has a market capitalization of $4.55 billion, a P/E ratio of -21.68 and a beta of 0.21. Celcuity, Inc. has a fifty-two week low of $44.42 and a fifty-two week high of $151.02. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). On average, equities analysts forecast that Celcuity, Inc. will post -4.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

CELC has been the topic of a number of recent research reports. Guggenheim upped their target price on Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Monday. Citizens Jmp reissued a “market outperform” rating and set a $177.00 price target on shares of Celcuity in a research report on Monday. Needham & Company LLC decreased their price objective on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Craig Hallum reaffirmed a “buy” rating and issued a $178.00 price objective on shares of Celcuity in a report on Wednesday, July 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $155.00 price objective on shares of Celcuity in a report on Friday, August 14th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $154.55.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.